sonrotoclax (Beqalzi)

From Aaushi

Jump to navigation Jump to search

^[1]

Indications

refractory mantle cell lymphoma
- adults previously treated with two or more lines of therapy that includes a BTK inhibitor

Mechanism of action

BCL2 inhibitor

More general terms

antineoplastic agent (chemotherapeutic agent)

References

↑ Bassett M Next-Gen BCL2 Inhibitor Approved for Aggressive Lymphoma. Sonrotoclax (Beqalzi) indicated for relapsed or refractory mantle cell lymphoma MedPage Today. May 13, 2026 https://www.medpagetoday.com/hematologyoncology/lymphoma/121256

Database

PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=149553242

Retrieved from "https://aaushi.info/w/index.php?title=A59591&oldid=1298322"

↑ Back to top